ANIFROLUMAB ( DrugBank: Anifrolumab )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2
49	全身性エリテマトーデス	39
53	シェーグレン症候群	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03435601 (ClinicalTrials.gov)	April 18, 2018	31/1/2018	A Study to Target the Type I IFN Receptor by Administrating Anifrolumabin RA Patients With a High IF ...	A Randomised, Double-blind, Placebo-controlled Phase II Study to Target the Type I IFN Receptor by A ...	Rheumatoid Arthritis	Drug: Anifrolumab;Drug: Placebos	Josef Smolen, Univ. Prof. Dr.	NULL	Recruiting	18 Years	70 Years	All	24	Phase 2	Austria
2	EUCTR2017-001717-92-AT (EUCTR)	11/12/2017	17/08/2017	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by a ...	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by a ...	High IFN siganture in patients with rheumatoid arthritis MedDRA version: 20.0;Level: PT;Classificati ...	Product Name: Anifrolumab(MEDI-546) INN or Proposed INN: ANIFROLUMAB Other descriptive name: ANIFROLUM ...	Medical University of Vienna	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	Austria;Switzerland;Italy

First Previous1Next Last

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 10 of 39 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05440422 (ClinicalTrials.gov)	March 22, 2023	29/6/2022	The Role of Anifrolumabin Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythem ...	The Role of Anifrolumabin Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythem ...	Systemic Lupus Erythematosus;Cardiovascular Disease;Premature Atherosclerosis	Drug: anifrolumab;Other: Placebo	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Not yet recruiting	18 Years	80 Years	All	45	Phase 1	United States
2	EUCTR2020-004529-22-DE (EUCTR)	21/04/2022	23/09/2021	Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Moderate-to-severe Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: ANIFROLUMAB Other descriptive nam ...	AstraZeneca	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Spain;Ukraine;Chile;Russian Federation;Colombia;United Kingdom;Hungary;Mexico;Argentin ...
3	JPRN-jRCT2071210076	03/03/2022	15/10/2021	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients ...	Systemic Lupus Erythematosus	Approximately 360 patients are planned to be randomly assigned in a 1:1 ratio (180 patients per treat ...	Hibi Kazushige	NULL	Recruiting	>= 18age old	<= 70age old	Both	36	Phase 3	United States;Argentina;Bulgaria;Chile;Colombia;Hungary;Mexico;Peru;Poland;Russia;Ukraine;United Kin ...
4	NCT04931563 (ClinicalTrials.gov)	September 13, 2021	29/4/2021	Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy ...	Active Systemic Lupus Erythematosus	Biological: Anifrolumab;Drug: placebo	AstraZeneca	NULL	Recruiting	18 Years	70 Years	All	328	Phase 3	China;Hong Kong;Korea, Republic of;Philippines;Taiwan;Thailand
5	EUCTR2020-004529-22-BG (EUCTR)	10/09/2021	23/07/2021	Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Moderate-to-severe Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: ANIFROLUMAB Other descriptive nam ...	AstraZeneca	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Spain;Ukraine;Chile;Russian Federation;Colombia;United Kingdom;Hungary;Mexico;Argentin ...
6	EUCTR2020-004529-22-HU (EUCTR)	24/08/2021	18/06/2021	Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Moderate-to-severe Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: ANIFROLUMAB Other descriptive nam ...	AstraZeneca	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Spain;Ukraine;Chile;Russian Federation;Colombia;United Kingdom;Hungary;Mexico;Argentin ...
7	NCT04750057 (ClinicalTrials.gov)	July 1, 2021	9/2/2021	Anifrolumab Early Access Program	An Early Access Program for AnifrolumabTreatment in Adult Patients With Active Systemic Lupus Erythe ...	Systemic Lupus Erythematosus	Drug: Anifrolumab	AstraZeneca	Clinigen, Inc.	No longer available	18 Years	N/A	All			NULL
8	NCT04877691 (ClinicalTrials.gov)	June 8, 2021	4/5/2021	Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Systemic Lupus Erythematosus	Drug: Medi-546;Drug: Placebo	AstraZeneca	Iqvia Pty Ltd	Recruiting	18 Years	70 Years	All	360	Phase 3	United States;Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Fed ...
9	NCT04726553 (ClinicalTrials.gov)	January 20, 2021	22/1/2021	Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE	Nature of AnifrolumabImpact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Act ...	Systemic Lupus Erythematosus (SLE)	Drug: Anifrolumab;Drug: Standard of Care	Oklahoma Medical Research Foundation	NYU Langone Health;Yale University;Piedmont Heart Institute, Inc., Atlanta, GA;Columbia University	Recruiting	18 Years	70 Years	All	20	Early Phase 1	United States
10	EUCTR2016-000625-39-BG (EUCTR)	17/05/2017	08/03/2017	A study to characterize the safety and tolerability of Anifrolumabin adult patients with Systemic Lu ...	A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise ...	Systemic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Syste ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: Anifrolumab	AstraZeneca AB	NULL	Not Recruiting			Female: yes Male: yes	575	Phase 3	United States;Taiwan;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Australia;P ...

First Previous1 2 3 4Next Last

先頭へ

53. シェーグレン症候群

臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05383677 (ClinicalTrials.gov)	October 1, 2022	29/3/2022	Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome	ANIfrolumabTreatment for 24 Weeks in Patients With Primary Sjögren's Syndrome - Efficacy and Safety ...	Sjogren's Syndrome	Drug: Anifrolumab;Drug: Placebo	University Medical Center Groningen	AstraZeneca	Recruiting	18 Years	N/A	All	30	Phase 2	Netherlands

First Previous1Next Last

先頭へ